Close Menu

Seegene

Invitae said this week that it completed its acquisition of Singular Bio on June 19.

QuantuMDx and Molbio Diagnostics said this week they have signed a memorandum of understanding to work jointly in infectious disease diagnostics.

Through the joint collaboration, Seegene plans to accelerate development of its random access system on Hamilton's automated liquid handling platforms.

The company's new QuantStudio 5 Dx Real-Time PCR system allows users to wield multi-modal software to detect pathogens.

The agreement with Mexico's agriculture department covers studies to evaluate molecular detection assays for bovine TB, as well as studies on zoonotic TB diagnosis.

The partnership marks the first step in the company's plan to develop 100 new molecular diagnostics within the next two years.

Seegene will use its proprietary assay development technologies to create highly multiplexed tests for the Hologic Fusion platform. 

The service — which Seegene plans to launch next year — boasts the specificity of fluorescently tagged probes at the cost of intercalating dyes.

Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.

The worldwide collaboration agreement is for co-development of multiplex real-time PCR reagents for the BD Max molecular diagnostics platform.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.